Lund University research group receives follow-on DKK 1 million grant from Novo Nordisk Foundation for diabetes-related studies with Follicum peptides

August 29, 2018

Lund University research group receives follow-on DKK 1 million grant from Novo Nordisk Foundation for diabetes-related studies with Follicum peptides

Follicum AB (“Follicum”) today announced that Professor Jan Nilsson’s research team at Lund University has received an additional DKK 1,000,000 funding from the Novo Nordisk Foundation for carrying out preclinical studies for Follicum’s diabetes project based on modified osteopontin-related peptides. This represents a follow-on grant from the estimated DKK 400,000 the group received in 2017. Follicum owns the right to the results generated in connection with the project.

The Novo Nordisk Foundation mainly supports research within e.g. biomedicine, biotechnology, general medicine and nursing at public research institutes. The sum of DKK 1 000 000 has been awarded for the project application entitled “Identification of osteopontin-related peptides stimulating insulin secretion”.

CEO Jan Alenfall comments`”This additonal grant from the Novo Nordisk Foundation is further proof that they regard the project as highly promising. We are delighted to be part of this exciting diabetes project in collaboration with Lund University.”

For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97
Email: info@follicum.com

This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 29th of August 2018.

About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com.

Open Press release